Frank Watanabe is the President, CEO and Director of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a commercial stage dermatology biotech company. Mr. Watanabe has extensive experience across general management, marketing, sales management and business development in US, international and global markets. Under his leadership, Arcutis grew from 3 staff to 350, raised more than $1.25 billion in private and public financings, built one of the industry’s leading dermatology pipelines, advanced multiple novel therapies from bench through Phase 3 development, and received US approval and launched their first product in Q3 2022, their second product in Q1 2024, and their third product in Q3 2024. Mr. Watanabe also is a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), and co-chairs the BIO advocacy working group. Prior to joining Arcutis, he was co-founder and Chief Operating Officer of Kanan Therapeutics, a cardiovascular drug development company, and before that, was Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals. Earlier in his career, he was an executive at Amgen, Inc., where he was involved in the development of Repatha® for hyperlipidemia and Aimovig® for migraine. Previously, he was an executive with Eli Lilly and company, and an official in the U.S. Government. He was also a commissioned officer in the U.S. Navy Reserves for 25 years. Mr. Watanabe earned his M.A. in National Security Studies, and his B.A. in International Relations, both at Georgetown University.